Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 17,841 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Breast Cancer Screening, Artificial Intelligence (AI)
Interventions: Artificial intelligence (AI) decision-support tool; Device
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 400,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 3 more

Conditions: Asthma
Interventions: Dulera; Drug
Lead sponsor: Asthma Management Systems; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions: Interpersonal Psychotherapy, Venlafaxine HCl ER; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions: Droxidopa, Atenolol, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Gastrointestinal Stromal Tumor
Interventions: sunitinib malate, imatinib mesylate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Detroit, Michigan • Farmington Hills, Michigan • City of Saint Peters, Missouri + 3 more

Conditions: Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions: Rapid respiratory pathogen nucleic acid amplification test; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 1 Year to 101 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions: iChoose Kidney Decision Aid; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York

Conditions: Overweight, Obesity
Interventions: Physical activity referral; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 6 Years to 18 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: San Francisco, California

Conditions: Bariatric Surgery
Interventions: Pressure controlled ventilation, Volume controlled ventilation, PRVC ventilation; Other
Lead sponsor: Joseph D. Tobias; Other
Eligibility: 14 Years to 20 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Abortion in First Trimester
Interventions: Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone; Drug
Lead sponsor: Study Investigator-Sponsor; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant tablet, Placebo tablet; Drug · Other
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 16 more

Conditions: Diabetic Foot Ulcer
Interventions: Amnio-Maxx; Other
Lead sponsor: Capsicure, LLC; Network
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Athens, Alabama • San Diego, California • Coral Gables, Florida + 9 more

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Chronic Kidney Disease
Interventions: interactive educational intervention; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Ischemic Stroke
Interventions: Acetylcysteine, Dextrose in Water; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Torrance, California

Conditions: Chronic Hepatitis B
Interventions: ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • New York, New York + 1 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more

Conditions: Osteo Arthritis Knee
Interventions: Guardian Sport Rehabilitator knee brace; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: T-817MA-H, T-817MA-L, Placebo; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 50
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Stanford, California • Orlando, Florida • Iowa City, Iowa + 5 more

Conditions: Surgery
Interventions: Routine Elective Surgery- In patient or out patient elective surgery, Blood test for genetic testing, Drug-genetic Profile; Procedure · Diagnostic Test · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Laryngopharyngeal Reflux
Interventions: Fosamprenavir Calcium, Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 64 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Labor Pain
Interventions: No Basal Infusion, Basal infusion, PCEA solution (bupivacaine and fentanyl); Other · Drug
Lead sponsor: Neil Roy Connelly, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Literacy, Burden, Caregiver, Health Care Utilization
Interventions: One-4-ALL Initiative, Control; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

Physical Activity Referrals to the Community

Modes of Ventilation During Laparoscopic Bariatric Surgery

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

Targeting Social Determinants to Improve Chronic Kidney Disease Care

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Utilization of a Knee Brace With Extension Swing

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

Telotristat Etiprate for Carcinoid Syndrome Therapy

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor

One-4-ALL Initiative